Hikma Pharmaceuticals Sustainability Profile
Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
DitchCarbon Score
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals's score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Pharmaceuticals's reported carbon emissions
In 2024, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 120,273,000 kg CO2e from Scope 1 and 2 combined, with Scope 1 emissions at about 38,469,000 kg CO2e and Scope 2 emissions at approximately 85,682,000 kg CO2e. The company also disclosed Scope 3 emissions amounting to about 42,606,000 kg CO2e. Hikma has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment reflects their ongoing efforts to enhance sustainability and reduce their carbon footprint. Since 2017, they have achieved a 4% reduction in reported GHG emissions from direct fuel usage and electricity consumption. The company aims to achieve net zero emissions by 2050, demonstrating a long-term commitment to climate action. These targets and achievements are part of Hikma's broader strategy to address climate change and contribute to a sustainable future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | - | - | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is Hikma Pharmaceuticals's Industry?
How Carbon Intensive is Hikma Pharmaceuticals's Location?
Hikma Pharmaceuticals's Scope 3 Categories Breakdown
Hikma Pharmaceuticals's Scope 3 emissions, which decreased by 95% last year and decreased by approximately 94% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 26% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 1599% of Scope 3 emissions.
Top Scope 3 Categories
Hikma Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hikma Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
